Non‐small cell lung cancer in China

P Chen, Y Liu, Y Wen, C Zhou - Cancer Communications, 2022 - Wiley Online Library
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Overcoming therapy resistance in EGFR-mutant lung cancer

A Passaro, PA Jänne, T Mok, S Peters - Nature Cancer, 2021 - nature.com
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Mutational signatures: emerging concepts, caveats and clinical applications

G Koh, A Degasperi, X Zou, S Momen… - Nature Reviews …, 2021 - nature.com
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics

P Song, LR Wu, YH Yan, JX Zhang, T Chu… - Nature biomedical …, 2022 - nature.com
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

[HTML][HTML] Non-invasive early detection of cancer four years before conventional diagnosis using a blood test

X Chen, J Gole, A Gore, Q He, M Lu, J Min… - Nature …, 2020 - nature.com
Early detection has the potential to reduce cancer mortality, but an effective screening test
must demonstrate asymptomatic cancer detection years before conventional diagnosis in a …

[HTML][HTML] Exosomes and cancer-Diagnostic and prognostic biomarkers and therapeutic vehicle

X Wang, L Tian, J Lu, IOL Ng - Oncogenesis, 2022 - nature.com
Exosomes belong to a subpopulation of extracellular vesicles secreted by the dynamic
multistep endocytosis process and carry diverse functional molecular cargoes, including …

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

L Buscail, B Bournet, P Cordelier - Nature reviews Gastroenterology & …, 2020 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Perioperative ctDNA-based molecular residual disease detection for non–small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)

L Xia, J Mei, R Kang, S Deng, Y Chen, Y Yang… - Clinical Cancer …, 2022 - AACR
Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …

[HTML][HTML] ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

A Dasari, VK Morris, CJ Allegra, C Atreya… - Nature reviews Clinical …, 2020 - nature.com
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

Genomic profiling for clinical decision making in lymphoid neoplasms

L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …